Traditional herbal medicine in preventing recurrence after resection of small hepatocellular carcinoma: a multicenter randomized controlled trial

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Ferlay, 2010 Ercolani, 2003, Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence, Ann Surg, 237, 536, 10.1097/01.SLA.0000059988.22416.F2 Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933 Imamura, 2003, Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy, J Hepatol, 38, 200, 10.1016/S0168-8278(02)00360-4 Jiang, 2003, Study for the clinical and pathological factors influencing the early postoperative recurrence of the small hepatocellular carcinoma, Lin Chuang Yu Shi Yan Bing Li Xue Za Zhi, 19, 258 Poon, 2002, Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation, Ann Surg, 235, 373, 10.1097/00000658-200203000-00009 Llovet, 2003, Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival, Hepatology, 37, 429, 10.1053/jhep.2003.50047 Takayama, 2000, Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial, Lancet, 356, 802, 10.1016/S0140-6736(00)02654-4 Lo, 2007, A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma, Ann Surg, 245, 831, 10.1097/01.sla.0000245829.00977.45 Schwartz, 2002, Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials, Lancet Oncol, 3, 593, 10.1016/S1470-2045(02)00873-2 Samuel, 2009, Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma, Cochrane Database Syst Rev, 10.1002/14651858.CD001199.pub2 Molassiotis, 2005, Use of complementary and alternative medicine in cancer patients: a European survey, Ann Oncol, 16, 655, 10.1093/annonc/mdi110 Gupta, 2005, The use of dietary supplements in a community hospital comprehensive cancer center: implications for conventional cancer care, Support Care Cancer, 13, 912, 10.1007/s00520-005-0820-9 Wu, 2003, Traditional Chinese medicine in prevention and treatment of liver cancer: function, status and existed problems, J Chin Integr Med, 1, 163, 10.3736/jcim20030302 Deng, 2004, Complementary therapies for cancer-related symptoms, J Support Oncol, 2, 419 Piao, 2004, Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial, Anticancer Res, 24, 303 Qi, 2010, Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells, J Ethnopharmacol, 128, 654, 10.1016/j.jep.2010.02.022 Xin, 2008, Two new polyoxygenated triterpenoids from Actinidia valvata., Helvetica Chimica Acta, 91, 575, 10.1002/hlca.200890060 Shim, 2004, Anti-angiogenic activity of a homoisoflavanone from Cremastra appendiculata., Planta Med, 70, 171, 10.1055/s-2004-815496 Liu, 2004, Chemical studies on two acidic polysaccharides from Salvia chinensis., Zhong Cao Yao, 35, 8 Meng, 2009, Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer, Cancer, 115, 5309, 10.1002/cncr.24602 Yu, 2009, The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula: a retrospective study, Cancer, 115, 5132, 10.1002/cncr.24567 Chen, 2006, A retrospective controlled analysis of outcomes of using integrated therapy of traditional Chinese and modern medicines for primary liver cancer of middle and late stages, J Altern Complement Med, 12, 941, 10.1089/acm.2006.12.941 Oken, 1982, Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, 649, 10.1097/00000421-198212000-00014 Altman, 2001, The revised CONSORT statement for reporting randomized trials: explanation and elaboration, Ann Intern Med, 134, 663, 10.7326/0003-4819-134-8-200104170-00012 Kumada, 1997, Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma, Hepatology, 25, 87, 10.1002/hep.510250116 Cancer Therapy Evaluation Program ICH Harmonised Tripartite Guideline, 1999, Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group, Stat Med, 18, 1905 1994, Strategy for model selection, 78 Wei, 2011, Clinical research on the recrudesce and prognosis of liver cancer with TACE, Youjiang Yi Xue, 39, 403 Su, 2003, Inhibition effects of three kinds of bufotoxins on human SMMC-7721 and BEL-7402 hepatoma cells lines, Di Er Jun Yi Da Xue Xue Bao, 24, 393 Han, 2004, Anti-tumor effects of bufalin on the orthotopic transplantation tumor model of hepatocellular carcinoma in mice, Zhonghua Shi Yan Wai Ke Za Zhi, 21, 1436 Cui, 2010, Anti-hepatitis B virus activities of cinobufacini and its active components bufalin and cinobufagin in HepG2. 2.15 cells, Biol Pharm Bull, 33, 1728, 10.1248/bpb.33.1728 Llovet, 2008, Novel advancements in the management of hepatocellular carcinoma in 2008, J Hepatol, 48, S20, 10.1016/j.jhep.2008.01.022 Ling, 2003, Problems in cancer treatment and major research of integrative medicine, J Chin Integr Med, 1, 168, 10.3736/jcim20030305